Oral Semaglutide and Cardiovascular Outcomes by Baseline A1c and BMI in People with Type 2 Diabetes in the SOUL Trial
Authors:
Silvio E. Inzucchi1; Rohana Abdul Ghani2; John Deanfield3; Mads D. M. Engelmann4; G. Kees Hovingh4; Ole K. Jeppesen4; Monika Kellerer5; Kabirdev Mandavya6; Johannes F. Mann7; Nikolaus Marx8; Chantal Mathieu9; Darren K. McGuire10; Viswanathan Mohan11; Sharon L. Mulvagh12; Rodica Pop-Busui13; Neil R. Poulter14; Maria Sejersten Ripa4; Gabriela Roman15; Róbinson Sánchez García16; Michael Shechter17; John B. Buse18on behalf of the SOUL Study Group